$181M Tendered in Gossamer Bio's Distressed Debt Exchange, Nearing Completion
Summary
Gossamer Bio announced that $181.05 million of its 5.00% Convertible Senior Notes due 2027 have been tendered in its distressed debt exchange, representing over 90% of the outstanding notes. This follows the company's recent disclosures of a going concern warning, a Nasdaq delisting notice, and dwindling cash. The exchange offer, which involves issuing up to $72 million in new secured notes and significant share dilution, is a critical measure to address the company's severe financial distress. The high tender rate is a positive indication that the exchange offer is likely to succeed, which is essential for the company's immediate financial viability and to potentially avert a more severe outcome. The final expiration deadline for the offer is June 16, with settlement expected on June 18.
At the time of this announcement, GOSS was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.5M. The 52-week trading range was $0.16 to $3.87. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.